iiinova — where your digital self keeps evolving

Ysios Capital Partners @ysioscapital.bsky.social · 28/07/2026

#YsiosReport I Ysios Capital’s 2025 / H1 2026 Review is out: strategic transactions, portfolio milestones and growth across the firm. 👉Explore the review ysioscapital.com/wp-content/u... #Biotech #LifeSciences #VC

020

Ysios Capital Partners @ysioscapital.bsky.social · 09/07/2026

#YsiosTeam I 🎉 Excited to announce Malgorzata Rogalska's promotion to #Associate at #YsiosCapital! 👏Congrats Malgorzata, well deserved! 🔗Full profile ysioscapital.com/team/malgorz... #vc #talent

000

Ysios Capital Partners @ysioscapital.bsky.social · 01/07/2026

#YsiosNews I #Ipsen to acquire our #portfolio company #MemoTherapeutics 🎯 #Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus infection in #kidney transplant recipients, a serious complication with no approved treatment. 👉 ysioscapital.com/2026/07/01/i... #vc

030

Ysios Capital Partners @ysioscapital.bsky.social · 04/06/2026

#YsiosNews I Ysios joins OnaTherapeutics $86.6M Series B to advance first-in-class #ADCs for treatment-resistant cancers. ✅ONA-255 #BreastCancer, toward clinical proof of concept ✅ONA-389 #ColorectalCancer ysioscapital.com/2026/06/04/o... #YsiosPortfolio #vc #biotech #barcelona

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

020

Ysios Capital Partners @ysioscapital.bsky.social · 21/05/2026

#PortfolioNews I Inbiomotion continues to expand its #international presence, with distribution partnerships spanning #Spain, #Portugal, #Italy, the #UK & Ireland, Sub-Saharan #Africa and now #SouthKorea. 👉https://buff.ly/OQsIayS #vc #breastcancer #oncology #ysiosportfolio

Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea

020

Ysios Capital Partners @ysioscapital.bsky.social · 27/03/2026

📢 #YsiosNews I #InceptionBio, a €100M target fund to drive #biotech #companycreation and #earlystage innovation, with a strong focus on #Spain 🔹First closing completed with CDTI Innovacion 🔹Target 3 new biotech companies in 2026 👉 buff.ly/evaem36 #vc #techtransfer

000

Ysios Capital Partners @ysioscapital.bsky.social · 23/03/2026

#Congress | Find us this week at 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 in Lisbon, Portugal! #BIOEuropeSpring 🙋 Representing Ysios Capital: Arturo Urrios and Malgorzata Rogalska, Ph.D. 🔗 lnkd.in/d7ZGGGHC 🤝 Let’s connect in Lisbon! #BIOEuropeSpring #Biotech #VentureCapital #Biopharma #EuropeanBiotech

010

Ysios Capital Partners @ysioscapital.bsky.social · 18/03/2026

#YsiosTeam I Ysios strengthens team to lead new early-stage vertical. 🚀 🎯Joan Perelló appointed Managing Partner and Arturo Urrios joins as Partner. Full details👉 buff.ly/NX14L8c #Talent #vc #YsiosTeam #Spain #Biotech

020

Ysios Capital Partners @ysioscapital.bsky.social · 09/02/2026

#PortfolioNews | Memo Therapeutics partners with CSL to advance recombinant polyclonal IgG, validating its DROPZYLLA® platform. 🚀🧬 👉 buff.ly/uCOUhUh #YsiosPortfolio

000

Ysios Capital Partners @ysioscapital.bsky.social · 16/01/2026

🔬#Portfolionews | Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI guidelines for early #breast #cancer. 🎯 Advancing MAF-based clinical decision-making! 👉 buff.ly/zSld1qQ #oncology #brestcancer

010

Reposted by Ysios Capital Partners

Biocat @biocat.cat · 10/12/2025

💡 Jordi Vidal (Kibo Ventures), Miriam Damas (Ship2B), Josep Miquel Torregrosa (Suma Capital) and Íñigo López-Huerta (@ysioscapital.bsky.social) share insights on purpose-driven venture capital. Don’t miss this session to discover how leading VCs invest with impact.

311

Ysios Capital Partners @ysioscapital.bsky.social · 07/11/2025

📢 #YsiosTeam | We are delighted to announce the promotion of Almudena Méndez and Sriram Balusu to #Associate at @ysioscapital.bsky.social ! 🎉 👏 Congratulations, very well deserved! 🙋‍♀️ Meet Almudena lnkd.in/dSrMw4Ya 🙋 Meet Sriram: bit.ly/SriramB #vc #talent

010

Ysios Capital Partners @ysioscapital.bsky.social · 07/11/2025

#Telescope I 🔭 The Q3 report for #TelescopeBiotech, a public equities fund advised by @ysioscapital.bsky.social , is now available from our partner Andbank Wealth Management. 👉Full report - andbank.es/boutiquehub/... #PublicEquity #Fund #healthcareInvesting #BiotechSector

010

Ysios Capital Partners @ysioscapital.bsky.social · 08/10/2025

#Speaker I Terminamos el día con nuestra analista Malgorzata Rogalska en el panel “Due Diligence Decoded: Diving into VC, CVC, and Pharma Practices” Programa completo 👉https://buff.ly/ajutCuH #BioSpain2025 #vc

000

Ysios Capital Partners @ysioscapital.bsky.social · 08/10/2025

#Speaker I Seguimos ahora con nuestro Partner Thomas Harth en el panel “Science Meets Capital: De-risking Early Biotech to Unlock Investment” Programa completo 👉https://amconferences.eventsair.com/QuickEventWebsitePortal/biospain-2025/program/Agenda #BioSpain2025 #vc

000

Ysios Capital Partners @ysioscapital.bsky.social · 08/10/2025

#Speaker I Hoy, nuestro Partner Guillem Laporta participa en "The Role of Biotechnology in the Pharmaceutical Industry: Present and Future Perspectives" Programa completo 👉https://amconferences.eventsair.com/QuickEventWebsitePortal/biospain-2025/program/Agenda #BioSpain2025 #vc

000

Ysios Capital Partners @ysioscapital.bsky.social · 07/10/2025

#Speaker I Hoy, nuestro Managing Partner Joë Jean-Mairet participa en "Guest Nation Switzerland: Entangling the Swiss and Spanish Biotech Ecosystems" Programa completo 👉 amconferences.eventsair.com/QuickEventWe... #BioSpain2025 #vc

030

Ysios Capital Partners @ysioscapital.bsky.social · 30/09/2025

#YsiosTeam I 🎉 Excited to announce Laura Argelich's promotion to #Associate at #YsiosCapital! 👏Congrats Laura, well deserved! 🔗Full profile ysioscapital.com/team/laura-a... #vc #talent

050

Ysios Capital Partners @ysioscapital.bsky.social · 18/09/2025

#PortfolioNews I Study shows that #MAFTest® developed by our #portfolio company #Ibiomotion may save €105M in early #breast #cancer care. 🔗 Press release - buff.ly/8pAhrip 📄 Full publication here: lnkd.in/d3aUWmpp #Oncology #HealthEconomics #BreastCancer

Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer

010

Reposted by Ysios Capital Partners

Diari ARA @ara.cat · 16/09/2025

El fons d'inversió Ysios Capital ha tancat un acord de compravenda amb la multinacional suïssa CSL per un preu màxim de 2.200 milions de dòlars (uns 1.862 milions d&...

ara.cat

Ysios tanca un acord de venda d'una 'start-up' per un màxim de 1.862 M€

La companyia participada pel fons d'inversió està desenvolupant un tractament contra les hemorràgies

021

Ysios Capital Partners @ysioscapital.bsky.social · 16/09/2025

📢 #PortfolioNews | Excited to share the strategic deal of our #portfolio company #VarmX with #CSL 💊 🔹Up to $2.2B incl. $117m upfront & milestones 🔹Global Phase 3 of VMX-C001 fully funded 🌍Step closer to market for a major unmet need 👉 buff.ly/aO4iHwV #YsiosPortfolio #vc

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

030

Ysios Capital Partners @ysioscapital.bsky.social · 18/07/2025

#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion ! 👉 Full details here - buff.ly/aT4nwud #BreastCancer #Oncology #PortfolioNews #MAFTest

010

Ysios Capital Partners @ysioscapital.bsky.social · 25/06/2025

#PODCAST I 🎙️ Inside Spain’s biggest biotech Series B ever: €119M for SpliceBio 🧬Hear how they built it from scratch, scaled fast & made history. With CEO Miquel Vila-Perelló & @jordixiol.bsky.social (Ysios Capital). 🎧 buff.ly/Cl9x8vL #YsiosPodcast #BiotechPillsWithJordi #vc

020

Ysios Capital Partners @ysioscapital.bsky.social · 11/06/2025

#PortfolioNews | Proud to join the $135M Series B of our #portfolio company #SpliceBio, the largest round ever raised by a Spanish biotech 🚀 🧬 Advance SB-007 for #StargardtDisease 🔬Expand #GeneticMedicine pipeline 👉 buff.ly/jey8g9O #VC #Biotech #Innovation #ProteinSplicing

130

Ysios Capital Partners @ysioscapital.bsky.social · 26/05/2025

#Speaker | Don’t miss Karen Wagner at #SwissHLG today at 13:35 ! 🎤 "Managing a portfolio of minority stakes – the view from venture capital" #VC #Biotech #PharmaDeals #LifeSciences

010

Reposted by Ysios Capital Partners

activos.bsky.social @activos.bsky.social · 21/05/2025

La biofarmacéutica suiza ReproNovo capta unos 57 millones de euros y abrirá sede en Barcelona

elperiodico.com

La biofarmacéutica suiza ReproNovo capta unos 57 millones de euros y abrirá sede en Barcelona

021

Ysios Capital Partners @ysioscapital.bsky.social · 21/05/2025

📢 We’re proud to join the $65M Series A of #ReproNovo, advancing Phase 2 therapies in #ReproductiveMedicine & #WomensHealth 🔬Two lead assets: 🔹RPN001 – male infertility 🔹RPN002 – adenomyosis & ART First step into this space for Ysios Capital 👉https://buff.ly/oHEegkT #vc

030

Ysios Capital Partners @ysioscapital.bsky.social · 13/05/2025

#Congress | Join us this week at 𝗕𝗶𝗼€q𝘂𝗶𝘁𝘆 𝗘𝘂𝗿𝗼𝗽𝗲 2025 in Bruges! 🙋‍♂️🙋‍♀️Joël Jean-Mairet, Karen Wagner, Thomas Harth, Laura Argelich, Sriram Balusu. 🎯Excited to be back at this leading event for biotech investors. #BioequityEurope #BEE25 #Biotech #VentureCapital

010

Ysios Capital Partners @ysioscapital.bsky.social · 06/05/2025

#Speaker I 🎤 Don’t miss Karen Wagner today at #SwissBiotechDay — 12:00 in Room Verseau! "Bridging Borders: Cross-Border Partnering in Biotech" #VC #Biotech #GlobalDeals

010

Reposted by Ysios Capital Partners

Biocat @biocat.cat · 24/04/2025

💡Com hauria de ser un fons de transferència tecnològica i de creació d’spin-offs biotecnològiques? 🗣️Joël Jean-Mairet, Managing Partner d’@ysioscapital.bsky.social ha compartit el model d’èxit que utilitzen per invertir en projectes científics i acompanyar-los fins a la creació d'empreses

011

Ysios Capital Partners @ysioscapital.bsky.social · 22/04/2025

#PortfolioNews | #SparingVision receives #FDA support to launch Phase II trial of SPVN06 in #GeographicAtrophy 🎯 #GA is an advanced form of dry age-related macular degeneration (dAMD) that leads to progressive and irreversible vision loss 👉 buff.ly/m0BlGti #GeneTherapy

000

Ysios Capital Partners @ysioscapital.bsky.social · 08/04/2025

#PortfolioNews I Our #portfolio company #Xeltis passes #EIC evaluation for potential €10M funding 🎯Developing regenerative implants to transform vascular surgery through natural tissue regeneration. 👉 buff.ly/rl7BP3W #vc #innovation #dialysis

010

Ysios Capital Partners @ysioscapital.bsky.social · 04/04/2025

#PortfolioNews I We’re excited to share that our #portfolio company #Anacond Biomed has enrolled the first U.S. patient in its ATHENA trial. 🎯 Developing next-generation #neurothrombectomy devices for acute ischemic #stroke 👉 buff.ly/vXEDmrK #vc #Spain #Medtech

020

Ysios Capital Partners @ysioscapital.bsky.social · 04/04/2025

#PortfolioNewsI We're proud to share that we've joined the oversubscribed $102M financing of our #portfolio company #NeuronaTherapeutics 🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders 👉 buff.ly/YHqiseP #vc #CNS

020

Ysios Capital Partners @ysioscapital.bsky.social · 02/04/2025

#YsiosTeam I We're thrilled to welcome #SriramBalusu to the @ysioscapital.bsky.social team in #Barcelona! 🎯As an #Analyst he will contribute to the Advisory team for the newly launched 𝙏𝙚𝙡𝙚𝙨𝙘𝙤𝙥𝙚 𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙁𝙪𝙣𝙙, managed by Andbank 👉https://bit.ly/SriramB #vc #talent

110

Ysios Capital Partners @ysioscapital.bsky.social · 01/04/2025

#Congress | See you today at the #RESIEurope Conference in #Barcelona! 🙋‍♀️🙋‍♀️ Laura Argelich , @mrogalska.bsky.social 🗓️ April 1, 2025 📍Barcelona 👉 buff.ly/dLLcpV9 🎯 Connect with early-stage #investors, #startups, and key players in #lifesciences and #healthcare. #VC #BCN #RESI2025

000

Ysios Capital Partners @ysioscapital.bsky.social · 13/03/2025

#PortfolioNews | SpliceBio doses the first patient in the Phase 1/2 ASTRA study of SB-007, the first dual AAV #GeneTherapy for #StargardtDisease! 🎯 Showcasing the power of #ProteinSplicing to tackle diseases caused by #LargeGenes mutations. 👉 buff.ly/HvB3bPR #VC

020

Ysios Capital Partners @ysioscapital.bsky.social · 13/03/2025

🚀 See you today at the #International #HealthInvestmentForum by @CataloniaHealth! 🔍 What attracts global investors? How can we make #Catalonia a top destination for health investments? Join the discussion! 🎤 Don’t miss the closing speech by our Managing Partner Joël Jean-Mairet.

010

Ysios Capital Partners @ysioscapital.bsky.social · 11/03/2025

#PortfolioNews | Our #quoted company Mineralys Therapeutics (Nasdaq: #MLYS) reports #positive Phase 3 & 2 results for #lorundrostat in #hypertension & announces a $250M #PublicOffering to advance R&D! 👉 buff.ly/qeyUu5K 👉 buff.ly/g18zKmA #ClinicalTrials

020

Ysios Capital Partners @ysioscapital.bsky.social · 06/03/2025

#PortfolioNews | NorthSea Therapeutics reports positive results from the Phase 2b ICONA trial of #Icosabutate in #MASH, published in the Journal of Hepatology! 📢 Read more: 👉 buff.ly/49eOq1j 📑 Full publication buff.ly/jZ9cXPW #vc #fibrosis #metabolic

010

Ysios Capital Partners @ysioscapital.bsky.social · 05/03/2025

#PortfolioNews I Our portfolio company #Minoryx Therapeutics has dosed the first patient in the Phase 2a TREE study of #leriglitazone for #RettSyndrome! 🧠 🗓️ Results expected in H12026 👉 buff.ly/NycHUxI #CNS #RareDisease #vc

010

Ysios Capital Partners @ysioscapital.bsky.social · 26/02/2025

#PortfolioNews | Adcendo receives #FDA clearance for Phase I trial of ADCE-T02 🎯 First-in-class #ADC targeting Tissue Factor in #SolidTumors. 🌍 Now recruiting in #Australia with #US expansion soon! 👉 Read more buff.ly/3Dc92qj #Onclogy #vc

010

Ysios Capital Partners @ysioscapital.bsky.social · 25/02/2025

#PortfolioNews | Our #portfolio company Neurona Therapeutics plans Phase3 trial in H2 2025 for NRTX-1001, a #celltherapy for drug-resistant #epilepsy. 🔬 Encouraging early data: Up to 97% seizure reduction with no cognitive impairment 📢 Read more: buff.ly/3Dh9kfv #VC

011